Sarcoma News

Loxo Oncology and Bayer have entered into a global partnership to develop and commercialize two targeted cancer therapies.

Raphael Pollock, MD, PhD, has been appointed interim director of The Ohio State University Comprehensive Cancer Center.

WAILEA, Hawaii — Single-agent lurbinectedin induced partial responses among patients with advanced Ewing sarcoma, according to results of multicenter phase 2 basket study presented at the Connective Tissue Oncology Society Annual Meeting.

WAILEA, Hawaii — Negative surgical margins correlated with improved long-term survival among patients with primary pleomorphic liposarcoma, according to study results presented at Connective Tissue Oncology Society Annual Meeting.

WAILEA, Hawaii — The combination of doxorubicin, ifosfamide and mesna significantly improved outcomes among patients with advanced soft tissue sarcomas compared with olaratumab plus doxorubicin, according to retrospective study results presented at Connective Tissue Oncology Society Annual Meeting.

WAILEA, Hawaii — TAS-115 induced stable disease among patients with osteosarcoma and rare soft tissue sarcoma subtypes, according to results from the expansion cohort of a phase 1 study presented at the Connective Tissue Oncology Society Annual Meeting.

WAILEA, Hawaii — DCC-2618 induced disease control, objective responses and prolonged stable disease among pretreated patients with gastrointestinal stromal tumors, according to results of a dose-escalation study presented at the Connective Tissue Oncology Society Annual Meeting.

WAILEA, Hawaii — Perioperative administration of Rh-Endostatin with traditional chemotherapy improved outcomes for patients with stage IIB osteosarcoma, according to study results presented at Connective Tissue Oncology Society.

WAILEA, Hawaii — A randomized phase 2 trial designed to assess the effect of cediranib for patients with alveolar soft part sarcoma met its primary endpoint, according to results of the CASPS trial presented at Connective Tissue Oncology Society Annual Meeting.

WAILEA, Hawaii — Most patients with desmoid tumors safely underwent surveillance only, although pain or tumor growth necessitated treatment for some patients, according to study results presented at the Connective Tissue Oncology Society Annual Meeting.